285
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Incyte's recently active trials. Comparator arms are excluded.
- Ruxolitinib Cream11 trials
- Povorcitinib10 trials
- Vehicle Cream8 trials
- Ruxolitinib8 trials
- INCB1236677 trials
- Pemigatinib5 trials
Upcoming readouts
Next primary completion dates among Incyte's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Apr 2027MAESTRA 1: A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Over…Phase 2
- Apr 2027A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Ol…Phase 3
- Jul 2027Progress: To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplas…Phase 2
- Aug 2027Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previo…Phase 2
- Sept 2027Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Au…Phase 2
- Sept 2027AXemplify-357: A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus…Phase 3
Top therapeutic areas
Conditions studied most often across Incyte's recently active trials.
- Solid Tumors7 trials
- Atopic Dermatitis6 trials
- Chronic Graft-versus-host-disease5 trials
- Hidradenitis Suppurativa (HS)5 trials
- Myeloproliferative Neoplasms5 trials
- NonSegmental Vitiligo4 trials
Incyte pipeline by phase
The main study drugs across 58 active trials Incyte leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 310 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Povorcitinib | 9 | 3 | Oct 2026 est. | NCT06855498 · NCT06516965 · NCT06516952 |
| tafasitamab | 6 | 1 | Aug 2027 est. | NCT05429268 · NCT04824092 · NCT04680052 |
| INCA034176 | 5 | 2 | Jan 2027 est. | NCT06821542 · NCT06585774 · NCT06263478 |
| INCB123667 | 5 | 4 | Jan 2027 est. | NCT07797283 · NCT07214779 · NCT07023627 |
| Ruxolitinib Cream | 5 | 3 | Oct 2026 est. | NCT06959225 · NCT06958211 · NCT06804811 |
| INCA033989 | 4 | 3 | Oct 2026 est. | NCT07623200 · NCT07448155 · NCT06034002 |
| INCB161734 | 3 | 2 | Oct 2026 est. | NCT07522073 · NCT07814404 · NCT06179160 |
| INCA33890 | 2 | 2 | Dec 2028 est. | NCT07284849 · NCT05836324 |
| Ruxolitinib | 2 | — | Sept 2027 est. | NCT06832618 · NCT02955940 |
| Tacrolimus (Tac) | 1 | 1 | Jan 2031 est. | NCT06615050 |
Phase 26 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| INCB000928 | 2 | 1 | Jul 2027 est. | NCT05090891 · NCT04455841 |
| INCB099280 | 2 | — | Sept 2026 est. | NCT05888844 · NCT05879822 |
| Axatilimab | 1 | — | Jun 2027 est. | NCT06388564 |
| INCA000585 | 1 | 1 | Sept 2027 est. | NCT07104565 |
| Parsaclisib | 1 | — | Nov 2026 est. | NCT04509700 |
| Retifanlimab | 1 | — | — | NCT05287113 |
Phase 18 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| INCA035784 | 1 | 1 | Mar 2028 est. | NCT07008118 |
| INCA036873 | 1 | 1 | Aug 2028 est. | NCT07195916 |
| INCA036978 | 1 | 1 | May 2030 est. | NCT07441694 |
| INCB0123667 | 1 | — | Jul 2027 est. | NCT05238922 |
| INCB057643 | 1 | — | Apr 2027 est. | NCT04279847 |
| INCB160058 | 1 | — | Oct 2028 est. | NCT06313593 |
| INCB186748 | 1 | — | Mar 2027 est. | NCT06818812 |
| Ponatinib | 1 | 1 | Feb 2028 est. | NCT03934372 |
Derived from 58 active trials Incyte leads; 58 name an intervention, folding into 24 phased drugs. This is ComplyRx's reading of the registry, not Incyte's own pipeline disclosure.
Incyte trials
The 50 most significant of Incyte's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaNCT05888844INCB099280 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 63 est. | 28 Sept 2026 |
| A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveNCT05879822INCB099280 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 73 est. | 30 Sept 2026 |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)NCT06959225Ruxolitinib Cream | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 580 est. | 9 Oct 2026 |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)NCT06958211Ruxolitinib Cream | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 573 est. | 9 Oct 2026 |
| A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male ParticipantsNCT07814404INCB161734 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 10 est. | 15 Oct 2026 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult ParticipantsNCT07448155INCA033989 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 126 est. | 19 Oct 2026 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)NCT06516952Povorcitinib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 349 est. | 19 Oct 2026 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)NCT06516965Povorcitinib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 346 est. | 19 Oct 2026 |
| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)NCT04509700Parsaclisib | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 112 est. | 5 Nov 2026 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaNCT05851443povorcitinib | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 247 est. | 20 Nov 2026 |
| Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaNCT07049575Ruxolitinib Cream | Phase 1 | Locked · track to reveal | OngoingRecruiting | 24 est. | 9 Dec 2026 |
| STOP-HS LTEA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaNCT06212999Povorcitinib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 617 est. | 26 Dec 2026 |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationNCT06179160INCB161734 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 710 est. | 1 Jan 2027 |
| A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal DiseaseNCT07559396INCB123667 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 16 est. | 4 Jan 2027 |
| A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHDNCT06843408INCA034176 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 32 est. | 6 Jan 2027 |
| A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationNCT06818812INCB186748 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 30 est. | 27 Mar 2027 |
| A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic ImpairmentNCT07559474INCB123667 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 16 est. | 13 Apr 2027 |
| MAESTRA 1A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionNCT07023627INCB123667 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 160 est. | 27 Apr 2027 |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental VitiligoNCT06804811Ruxolitinib Cream | Phase 3 | Locked · track to reveal | OngoingRecruiting | 250 est. | 30 Apr 2027 |
| LIMBERSafety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsNCT04279847INCB057643 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 140 est. | 30 Apr 2027 |
| A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseNCT06388564Axatilimab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 130 est. | 1 Jun 2027 |
| Study of INCB123667 in Subjects With Advanced Solid TumorsNCT05238922INCB0123667 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 291 est. | 27 Jul 2027 |
| ProgressTo Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaNCT05090891INCB000928 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 98 est. | 30 Jul 2027 |
| An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database AnalysisNCT06627335Ruxolitinib Cream | — | Not yet scored | OngoingRecruiting | 5,621 est. | 15 Aug 2027 |
| Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabNCT06465433Tafasitamab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 25 est. | 29 Aug 2027 |
| Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersNCT07104565INCA000585 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 56 est. | 23 Sept 2027 |
| AXemplify-357A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseNCT06585774INCA034176 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 240 est. | 28 Sept 2027 |
| An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibNCT02955940Ruxolitinib | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 10 est. | 30 Sept 2027 |
| THRIVEObservational Study for Patients at Risk for Chronic Graft-Versus-Host DiseaseNCT05919511Non-Interventional | — | Not yet scored | OngoingRecruiting | 1,500 est. | 15 Oct 2027 |
| STOP-LTRRollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibNCT06855498povorcitinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 600 est. | 28 Feb 2028 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsNCT05936359INCA033989 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 160 est. | 29 Feb 2028 |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative NeoplasmsNCT07008118INCA035784 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 120 est. | 14 Mar 2028 |
| Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaNCT07213973Povorcitinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 40 est. | 25 Mar 2028 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic TherapyNCT06821542INCA034176 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 9 est. | 31 May 2028 |
| TRuE-VIP1A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental VitiligoNCT06548360Ruxolitinib Cream | Phase 3 | Locked · track to reveal | OngoingRecruiting | 180 est. | 5 Jun 2028 |
| A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesNCT07195916INCA036873 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 280 est. | 18 Aug 2028 |
| DAWN-303A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaNCT07522073INCB161734 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 588 est. | 15 Sept 2028 |
| A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative NeoplasmsNCT06313593INCB160058 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 37 est. | 9 Oct 2028 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsNCT06034002INCA033989 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 290 est. | 29 Oct 2028 |
| MAESTRA 2Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionNCT07214779INCB123667 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 466 est. | 15 Nov 2028 |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerNCT07284849INCA33890 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 700 est. | 29 Dec 2028 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)NCT07124078INCA034176 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 60 est. | 31 Jan 2029 |
| A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsNCT05836324INCA33890 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 570 est. | 3 May 2029 |
| NEXERA-204A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and ChemotherapyNCT07823322INCA33890 | Phase 2 | Not yet scored | OngoingNot yet recruiting | 40 est. | 14 May 2029 |
| EXCALIBUR-ET2A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaNCT07623200INCA033989 | Phase 3 | Not yet scored | OngoingRecruiting | 426 est. | 15 Jun 2029 |
| Study of INCA036978 in Participants With Myeloproliferative NeoplasmsNCT07441694INCA036978 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 218 est. | 24 May 2030 |
| A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)NCT06615050Tacrolimus (Tac) | Phase 3 | Locked · track to reveal | OngoingRecruiting | 572 est. | 17 Jan 2031 |
| MAESTRA 3Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1NCT07797283INCB123667 | Phase 3 | Not yet scored | OngoingNot yet recruiting | 590 est. | 1 May 2032 |
| OPERA-1Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control PopulationNCT06259669Ruxolitinib Cream | — | Not yet scored | OngoingRecruiting | 958 est. | 1 Aug 2032 |
| A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult ParticipantsNCT07588139Povorcitinib | Phase 1 | Locked · track to reveal | OngoingRecruiting | 24 est. | 3 Sept 2026 |